Callan Capital LLC Has $441,000 Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Callan Capital LLC grew its position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 11.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 101,575 shares of the company’s stock after purchasing an additional 10,108 shares during the quarter. Callan Capital LLC owned approximately 0.20% of Cardiff Oncology worth $441,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in CRDF. GSA Capital Partners LLP boosted its stake in shares of Cardiff Oncology by 432.7% during the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after purchasing an additional 151,613 shares in the last quarter. Barclays PLC raised its position in shares of Cardiff Oncology by 291.9% during the third quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after acquiring an additional 39,542 shares during the last quarter. XTX Topco Ltd raised its position in shares of Cardiff Oncology by 44.3% during the third quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock worth $321,000 after acquiring an additional 36,947 shares during the last quarter. State Street Corp raised its position in shares of Cardiff Oncology by 3.4% during the third quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after acquiring an additional 27,628 shares during the last quarter. Finally, HB Wealth Management LLC bought a new position in shares of Cardiff Oncology during the fourth quarter worth about $105,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CRDF shares. Piper Sandler raised their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. HC Wainwright lowered their price objective on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, November 8th.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $4.75 on Friday. The company has a market cap of $242.87 million, a P/E ratio of -5.05 and a beta of 1.77. The stock has a 50 day simple moving average of $4.08 and a two-hundred day simple moving average of $3.16. Cardiff Oncology, Inc. has a fifty-two week low of $1.65 and a fifty-two week high of $6.42.

Insiders Place Their Bets

In other Cardiff Oncology news, Director Gary W. Pace bought 350,115 shares of the stock in a transaction on Wednesday, December 11th. The stock was acquired at an average cost of $2.60 per share, for a total transaction of $910,299.00. Following the completion of the acquisition, the director now owns 1,047,876 shares in the company, valued at $2,724,477.60. This trade represents a 50.18 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 7.80% of the stock is currently owned by corporate insiders.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.